Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5463_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
12.10.2026
Размер:
6 Мб
Скачать
☆
108
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2

2020).
Rutin is a lipophilic compound that is a potent antioxidant used as a treat-
      


 
pass metabolism (V iskupicova et al., 2015). Rutin has an increased tar geting

nanoparticles using the ionotropic gelation method, as it expressed improved
    

model (Ahmad et al., 2019a).
      Glycyrrhiza glabra are
another antioxidant and neuroprotective agent that may be used as a

caprolactone loaded nanoparticles, administered intranasally, increased
         -
     
       
(Ahmad et al., 2019b).


       

by coupled bimodal single-photon emission computed tomography (
   
          -
       
acute migraine management, this mucoadhesive nanoemulsion preparation
         






marketed drugs (Girotra et al., 2017).
Natural Biocarriers for Brain Targeting
109
        
       -
     







        
Box–Behnken design (Shah et al., 2016a).
Chitosan nanocarriers have also been used to treat depression, as demon-

antidepressant. When used intranasally, chitosan-loaded nanocarriers





       
by encapsulating it in chitosan and cyclodextrin intranasal microemulsion,

(Bshara et al., 2014).
          


popularity (Lou et al., 2009).
       
  
chitosan and polyethyleneimine-coated magnetic micelles nanoparticles,
a potential magnetic resonance imaging contrast agent, to deliver DNA to
         -
paramagnetic iron oxide nanoparticles in the chitosan-based nanoparticles

be delivered to the brain and potentially imaged using magnetic resonance



110
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
TABLE 4.1 
Disease Drug Investigated delivery system/special
comment
References

disease
Memantine Chitosan nanoparticles prepared by gamma



al. 2020)
Curcumin- and
dexamethasone


vasculature and high permeation to the
blood–brain barrier endothelium.

et al. 2014)
 

intranasal administration.
(Bshara et al.
2014)
Rivastigmine Chitosan-based mucoadhesive microemul-

and achieved brain targeting via intranasal
delivery route.
(Shah et al.
2018)
Epilepsy  
chitosan nanoparticles resulted in enhanced

administration.
(Liu et al.
2018)
Brain
ischemia
Rutin Rutin-loaded chitosan nanoparticles


administration.
(Ahmad et al.
2019a)
Migraine Nystatin 


(Girotra et al.
2017)
 
tripolyphosphate nanoparticles prepared

administration.
(Mandlik et
al. 2018)



intravenous or the nasal solution.
(Abdou et al.
2017)

disease
Dopamine Chitosan-dopamine or chitosan tyrosine
-


(Cassano et
al. 2020)
Rotigotine Rotigotine-loaded chitosan nanoparticles

-

(Bhattamisra
et al. 2020)
Natural Biocarriers for Brain Targeting
111
Disease Drug Investigated delivery system/special
comment
References
Rasagiline Encapsulating rasagiline in chitosan nanopar-
ticles using an ionic gelation technique
dramatically increases bioavailability in the

(Mittal et al.
2016)
Ropinirole
hydrochloride



could enhance the drug permeation across the
cellular membranes using the intranasal route.
(Pardeshi and

2018)
Psychiatric
disorder
Quetiapine








(Shah et al.
2016a)


ionic gelation method using Box–Behnken
design.
-


intranasal route.
(Shah et al.
2016b)
 Poly(lactic-co-glycolic acid)– chitosan

-

the nasal route.

2016)
Buspirone
hydrochloride
Chitosan and cyclodextrin intranasal micro-
emulsion, administrated via the intranasal
route revealed plasma concentration peaked at

(Bshara et al.
2014)


Reporter DNA


intranasally.
(Das et al.
2014)

Hyaluronic acid, given the name hyaluronan, is a natural polysaccharide

TABLE 4.1 (Continued)
112
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2

in the central and peripheral nervous system (Bayer, 2020). It regulates the
        

   
     
motility ( 
   






nervous system disorders.
   
        




     



        
strategy (Wang et al., 2022).
In another study conducted by Lu et al., hyaluronic acid-based hydrogel

          
-
   







Natural Biocarriers for Brain Targeting
113

  
prepared gel. In addition, the in vivo
       


Other investigated delivery systems based on hyaluronic acid involved

loaded hyaluronic acid nanoparticles to convey neuroglobin through the




their cellular uptake by endocytosis, in addition to their positive charge
  
       





-
chyma (Blanco et al., 2020).


-



       
        
    

        
      

      
      

114
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
TABLE 4.2        

Disease Drug Special comment References


Mesenchymal stem
cells and nerve



and other tissue repair therapy.
(Wang et al.,
2022)

(a peptide that
mimicvascular





(Lu et al.,
2019)
Gallic acid 





al., 2022b)







(Duan et al.,
2016)
Stem cells 

(Li et al.,
2020)
Brain
ischemia
Neuroglobin 

neuroprotective protein.

neuroprotective oxygen-sensing protein
(neuroglobin protein) to the damaged

(Blanco et
al., 2020)


-
           
-


         
chitosan. In contrast to the intranasal solution and oral tablet, the results

Natural Biocarriers for Brain Targeting
115


immobility (Haque et al., 2014).

      
   
        
       
       


(Lv et al., 2018).

    
used to treat various neurological diseases to achieve a greater therapeutic

-
   
     
-
         



  
       


4.2.2 PROTEIN CARRIERS

-


116
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
using either animal-derived or plant-derived source proteins. Animal

       

      



Being the most abundant protein in human body, albumin is considered
         

biocompatible, biodegradable, and nontoxic, in addition to the abundance
    -

2020). Several researchers have investigated albumin-based nanoparticles as

       
      
-

-
      


  



        


        




edema (Xue et al., 2020).
Natural Biocarriers for Brain Targeting
117
   -
          
     
       




          
        
      

      



to augment drug delivery to the brain (Rich et al., 2020).
Gao et al. prepared curcumin-loaded human serum albumin nanoparticles


        



-


-




the brain (Gao et al., 2020).
     -
        
        
        
biopolymer-based nanocarriers to increase drug permeability to the brain.
  